Wednesday, 24 April 2013 16:46
Share
Prof. Pierre Rustin
Hum Mol Genet. 2013 Apr 19.
Bayot A, Reichman S, Lebon S, Csaba Z, Aubry L, Sterkers G, Husson I, Rak M, Rustin P.
Source Hôpital Robert Debré, INSERM UMR 676
Abstract
Friedreich's ataxia (FRDA) is a progressive neurodegenerative disease characterized by ataxia, variously associating heart disease, diabetes mellitus and/or glucose intolerance. It results from intronic expansion of GAA triplet repeats at the FXN locus. Homozygous expansions cause silencing of the FXN gene and subsequent decreased expression of the encoded mitochondrial frataxin. Detailed analyses in fibroblasts and neuronal tissues from FRDA patients have revealed profound cytoskeleton anomalies. So far, however, the molecular mechanism underlying these cytoskeleton defects remains unknown. We show here that gene silencing spreads in cis over the PIP5K1B gene in cells from FRDA patients (circulating lymphocytes and primary fibroblasts), correlating with expanded GAA repeat size. PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase ? type I (pip5k1?), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].
Last Updated on Wednesday, 24 April 2013 17:06
Read more...
|
Saturday, 16 February 2013 19:48
Share
Dr Stefano Gustincich
Published on January 31, 2013
News kindly supplied by Kreso Babic
One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function. This novel technology is based on pioneering research in the lab of Dr Stefano Gustincich at SISSA in Trieste. The mechanism relies on the discovery of an entirely new function for RNA. Although most well known as a messenger RNA molecule made by genes for protein synthesis, most RNA is not actually made by genes. Once thought to be junk, important functions for non-coding RNA are increasingly being found.
Last Updated on Monday, 18 February 2013 22:59
Read more...
Monday, 21 January 2013 17:40
Share
FARA Clinical Research Network investigator Theresa A. Zesiewicz, MD
Published on January 7, 2013 at 7:01 AM •
Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "Safety and Efficacy Study of EPI-743 on Visual Function in Patients with Friedreich's Ataxia."
The trial is a placebo-controlled study lasting six months, followed by an extension phase in which all subjects will receive EPI-743. Subjects must be between 18 and 45 years of age, possess genetic confirmation of Friedreich's ataxia, and meet certain disease severity criteria. The primary endpoint of the trial is visual function, with secondary endpoints including neurological and neuromuscular function and disease-relevant biomarkers. More information on study specifics is available on ClinicalTrials.gov. This trial is being conducted with the assistance of investigators from the Friedreich's Ataxia Research Alliance (FARA) Clinical Research Network and FARA's Patient Registry. "FARA is excited about the commencement of the EPI-743 Friedreich's ataxia clinical trial, and is working closely with Edison Pharmaceuticals and Clinical Research Network investigators to expedite enrollment," stated FARA President Ronald Bartek . "This trial represents the importance of public-private partnership in drug development and the culmination of FARA-sponsored translational research, initiated with both FARA and National Institutes of Health (NIH) support."
Source/read more
|
Friday, 21 December 2012 22:39
Share
Dr Julie Greenfield
By Dr Julie Greenfield, Ataxia UK
A series of lay presentations were given by international ataxia researchers for the euro-ATAXIA conference. These are summarised below.
Update on recessive ataxias - Professor Michel Koenig (Strasbourg, France). Prof Michel Koenig from the University of Strasbourg began with an update on the non-Friedreich’s recessive ataxias and improving diagnosis. Screening to find the genes responsible for an individual’s ataxia is a difficult problem as there is no specific pathway linked to recessive ataxia. Rather, sensory nerve cells and nerve cells in the cerebellum are vulnerable in a number of different ways. He described next generation sequencing as a technological advance that will help in providing patients with specific diagnoses and highlighted how many new types of recessive ataxia are emerging, often very rare forms. Some newer conditions were described in some more detail. ARCA1, for example, is a pure ataxia only identified in Canada so far. He thought that the reason for not having identified other families is probably due to the technical difficult and high cost in finding mutations in this gene due to it being such a large size. ARCA2 is an ataxia associated with CoQ10 deficiency that could potentially respond to CoQ10 supplementation; and finally ARCA3 is a new entity which is associated with late onset, slow progression and a pure ataxia.
Can we manipulate our own stem cells and could this be a future therapy for the ataxias? Professor Silvia Marino (Barts and the London School of Medicine and Dentistry, UK).
Last Updated on Friday, 21 December 2012 23:28
Read more...
Friday, 21 December 2012 19:45
Share
THE INTERNATIONAL LITERARY PROJECT AGAINST FRIEDREICH’S ATAXIA Tel.: (+34) 637046067 - (+34) 91 632 14 09 E-mail: coordination@babelfamily.org
The realization of the BabelFAmily INTERNATIONAL LITERARY PROJECT!
In December 2010, Maria Blasco Gamarra, writer and someone who has Friedreich’s Ataxia, contacted the BABELFAMILY association. She wanted to share an ambitious idea with us: to write a novel with other authors from all over the world who, like her, suffer from Friedreich’s Ataxia, and to donate the profits to the biomedical research into curing the illness. The authors could write in their maternal language, since the work would be translated by a team of volunteer translators from BabelFAmily into several languages. On her initiative, other writers got on board: Fátima D’Oliveira (Portugal), Marguerite Black (South Africa), Maria Pino Brumberg, Eva and Diego Plaza Gonzalez, Ramon Herreruela Roldán, Inmaculada Priego Priego, Ana Pilar Tolosana, Kristina Zarrantz Elizalde and Maria Luz Gonzalez Casas (Spain), Jamie Leigh Hansen and Susan C. Allen (U.S.), Nicola Batty and Sarah Allen (UK), Claudia Parada (Mexico) and Rebecca Stant (Australia). Each author wrote a chapter of the book following a simple storyline which acted as a guiding thread bringing unity to a story without constraining the creative freedom or writing style of each author. A journey in time and space which uncovers an enigma, a terrible secret buried for more than a century. During this journey spanning two years, the writers have shared hopes and joys and many experiences which have enriched personal and literary experiences, but they have also mourned the death of fellow writer Nicola Batty, who unfortunately could not overcome the last crisis of Friedreich's ataxia. "We hope that where you are now is as beautiful as your prose."
Read more...
|
|
|
|
|
|
Page 1 of 2 |